Induced Pluripotent Stem Cells (iPSC)

Induced pluripotent stem cells are ordinary adult cells, commonly skin fibroblasts or blood cells, that scientists reprogram in the lab back to a pluripotent state resembling embryonic stem cells. Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University achieved this first in mouse cells in 2006 by introducing four transcription factors, now called the Yamanaka factors, and repeated the feat in human cells in 2007 [1][2]. James Thomson's group at the University of Wisconsin published an independent human reprogramming method the same year using a different but overlapping factor combination. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon for the discovery that mature, differentiated cells can be reprogrammed to a pluripotent state [3][4].

iPSCs solve two problems that limited embryonic stem cell research. They avoid destroying an embryo, sidestepping the ethical and funding fights described on our embryonic stem cell page, and they can be derived from a patient's own tissue, opening the door to autologous, genetically matched cell therapy that does not require lifelong immunosuppression. Both properties made iPSCs a major focus of disease modeling and drug discovery: researchers can take skin cells from a patient with a genetic disease, reprogram them to iPSCs, differentiate them into the affected cell type such as neurons or heart cells, and study the disease directly in a dish [1].

Clinical translation has accelerated markedly in the past few years. A Kyoto University team led by Jun Takahashi published Phase I/II trial results in Nature in 2025 describing allogeneic iPSC-derived dopaminergic progenitor cell transplantation for Parkinson's disease, building on earlier work showing these cells produce dopamine and improve motor symptoms in non-human primate Parkinson's models [5][6]. A separate program from Scripps Research scientist Jeanne Loring uses autologous iPSC-derived dopamine neuron precursors, with interim clinical findings from a Phase 1/2a trial presented at the 2026 ISSCR annual meeting [7].

iPSC-derived cell therapy has also entered the diabetes field. Chinese researchers at Shanghai Changzheng Hospital reported in Cell in September 2024 what they described as the first case of a person with type 1 diabetes achieving sustained insulin independence after transplantation of islet cells derived from chemically induced pluripotent stem cells, or CiPSC-islets, made from the patient's own reprogrammed cells [8][9]. This was a single-patient case report, not a controlled trial, and safety data came from prior nonhuman primate studies showing no tumor formation over long-term observation [9]. Chinese state media later described a related endoderm stem cell-derived islet program, E-islet, entering broader clinical evaluation in 2026 [10].

Regulatory recognition is starting to catch up. In January 2026, China-based iRegene Therapeutics announced its NouvNeu001 iPSC-derived therapy received FDA Regenerative Medicine Advanced Therapy designation alongside Fast Track designation, which the company described as the first iPSC therapy to hold both designations simultaneously [11]. RMAT designation speeds up FDA review interactions but does not itself constitute approval.

The safety profile of iPSC therapy carries a specific theoretical risk not shared by MSC products: because iPSCs are fully pluripotent, incompletely differentiated cells that escape into a transplant population carry a higher theoretical risk of forming teratomas, tumors made of disorganized mixed tissue types. Manufacturing protocols for clinical-grade iPSC products are built specifically to screen out residual undifferentiated cells before transplant, and none of the human trials published to date have reported tumor formation, but this remains an active area of manufacturing quality control rather than a fully solved problem [1][5].

No iPSC-derived therapy holds full FDA or EMA approval as of mid-2026. The field sits squarely in tier 3 of our evidence framework: early, promising human trial data with real biological plausibility, but not yet the large, controlled, replicated trials needed for tier 1 or 2 status.

A September 2026 review by Lucía Sánchez, Candela Magalí Rodriguez, and Fernando J Pitossi examined graft survival and neuroinflammation in pluripotent-stem-cell therapies for the central nervous system [12]. It describes Japan’s conditional approval of an iPSC-derived dopaminergic progenitor transplant for Parkinson’s disease and emphasizes TNF-alpha as a context-dependent determinant of progenitor differentiation and survival. The authors warn that non-selective anti-TNF drugs could interact unpredictably with grafts and discuss more specific pathway modulators as research candidates [12]. This is a review, not new clinical efficacy evidence. Conditional approval is not the same as broad approval or proof of long-term safety. Tumor risk, graft overgrowth, immune rejection, off-target differentiation, and durability remain central concerns.

A September 2026 Research Square preprint compared endothelial progenitor cells derived from induced pluripotent stem cells made from three neonatal and three mature donors [13]. The mature-donor lines formed less connected and less lumenized vascular networks in vitro. Donor age was associated with methylation, transcriptomic, and mitochondrial differences, including higher mitochondrial reactive oxygen species and lower membrane potential. An antioxidant improved network formation in the tested mature lines. This is a small preclinical comparison, not a human treatment study. It supports donor-age and manufacturing-quality checks for iPSC-derived vascular products, but it does not establish clinical efficacy or remove tumor, immune, or durability concerns.